Drug intelligence / Profile preview

HSC100

Development stage: Unknown
Lead developer: Tacitus Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

HSC100 is an investigational allogeneic hematopoietic stem cell therapy consisting of CD34-positive hematopoietic stem cells expanded ex vivo from umbilical cord blood using an epigenetic modulation platform. It is being developed to improve engraftment and reduce graft failure in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies, addressing the historical limitation of low stem cell dose in single cord blood units by expanding both the number and quality of transplantable stem cells.[1][4][7]

Beyond the preview

Go deeper on HSC100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSC100.

Explore the full profile